Clinical Trial Update: Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating 68Ga-PSMA PET-CT for detection of prostate cancer recurrence and its impact on patient management has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA PET/CT (68Ga-PSMA PET/CT imaging agent)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Prostate Cancers | Phase 2 | Status: WITHDRAWN